It has been reported that blocking MyD88, the downstream adapter protein for TLR4 signaling, significantly improves mortality and reduces oxidation-CaMK II expression and cardiac hypertrophy (15). The gene discussed is CAMK2G; the disease is cardiac hypertrophy.